Idiopathic Pulmonary Fibrosis – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disorder characterized by an irreversible loss of lung function. Pirfenidone was the first disease-modifying therapy (DMT) approved for IPF, followed soon after nintedanib (Ofev) by Boehringer Ingelheim. These therapies set the stage for fierce competition in the IPF therapy market. We explore this evolving space by examining current medical practice, including the clinical and commercial outlook for pirfenidone and nintedanib (Ofev); identifying the areas of pressing unmet need in the treatment of IPF; and assessing emerging therapies, including United Therapeutics’ treprostinil (inhaled), Boehringer Ingelheim’s PO-administered BI-1015550, Bristol Myers Squibb’s PO-administered BMS-986278, and EmphyCorp’s N115 (sodium pyruvate).
Questions answered
- How will the size of the IPF population change through 2033? How large are the key subpopulations? What percentage of the IPF population receives drug treatment?
- How do interviewed experts view the clinical profiles of pirfenidone and nintedanib (Ofev), and what factors drive or constrain their use? What are the most pressing clinical needs in the management of IPF, according to experts?
- Which emerging therapies do IPF experts consider most promising? If approved, how would emerging therapies influence the management of IPF and the market positions of pirfenidone and nintedanib (Ofev)? What is the commercial potential of treprostinil (inhaled), BI-1015550, BMS-986278, and N115 (sodium pyruvate)?
Product description
Niche & Rare Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Key feature
Niche & Rare Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Idiopathic Pulmonary Fibrosis - Landscape & Forecast - Niche & Rare Disease Landscape & Forecast (US/EU5)
- Executive Summary
- Commercial Outlook and Forecast
- Disease Context
- Epidemiology
- Current Treatment
- Emerging Therapies
- Drug Pipeline
- Methodology
- Bottom-up forecasting overview
- Bottom-up forecast key events and assumptions
- Market events impacting the idiopathic pulmonary fibrosis forecast
- Drug-treatment rate assumptions in idiopathic pulmonary fibrosis
- Forecast market authorization dates of key emerging therapies for the treatment of idiopathic pulmonary fibrosis
- Generic erosion
- Generic erosion assumptions
- Dosing assumptions of key therapies in idiopathic pulmonary fibrosis
- Days of therapy and compliance
- Emerging therapy prices
- Prices of key current and emerging therapies used to treat idiopathic pulmonary fibrosis
- Bottom-up forecast methodology
- Primary market research
- Appendix
- Content announcement
- Executive Summary
